Abstract Search

Background: The prescription of triiodothyronine (T3) for hypothyroidism is increasing worldwide, however, long-term effects of its use are largely unknown. Previous studies have suggested possible association between T3 use and breast cancer. The aim of the study was to examine the effects of T3 use on cancer incidence and mortality.Material: Our sample included the full adult population of individuals living in Sweden with at least three purchases of t...

0 shares

ea0070oc3.3 | Diabetes, Obesity, Metabolism and Nutrition | ECE2020

Circulating follistatin predicts type 2 diabetes risk

Wu Chuanyan , Borné Yan , Gao Rui , López Rodriguez Maykel , Roell William , Wilson Jonathan , Ahlqvist Emma , Luan Cheng , Peter Andreas , Machann Jürgen , Hong Mun-Gwan , Schwenk Jochen , Nilsson Peter , Shore Angela , Khan Faisel , Natali Andrea , Melander Olle , Orho-Melander Marju , Nilsson Jan , Renström Erik , Wollheim Claes , Pearson Ewan , Franks Paul , White Morris , Duffin Kevin , Vaag Allan , Laakso Markku , Stefan Norbert , Groop Leif , De Marinis Yang

Follistatin is a hepatokine found to be elevated in patients with type 2 diabetes (T2D) and promotes hyperglycemia in mice. We report that elevated baseline circulating follistatin levels predict future T2D incidence in longitudinal cohorts including up to 5274 individuals. Individuals with elevated circulating follistatin had higher risk of developing type 2 diabetes during follow-up of 4 years (IMI-DIRECT-METSIM, n = 1079, Finland), 5 and 19 years (MDC-CC, n...

0 shares

Endocrine Abstracts

Triiodothyronine (T3) use in hypothyroidism and effects on cancer and mortality

Circulating follistatin predicts type 2 diabetes risk

BiosciAbstracts